mTOR Signaling in Disease and Therapy

Dear Colleagues,

The mammalian target of rapamycin (mTOR) signaling is an indispensable kinase cascade which regulates the development and homeostasis of mammalian tissues through multiple biological mechanisms. mTOR works with other components to form distinct protein complex 1 (mTORC1) and complex 2 (mTORC2) functions as a regulator of cell growth, cell mobility, cell survival, autophagy, protein synthesis, and gene transcription. In this regard, as the dysregulation of mTOR signaling is implicated in the pathogenesis of many human diseases, targeting mTOR signaling is a unique therapeutic approach for disease management.  

We are pleased to invite you to submit your work on mTOR-mediated pathogenesis and the mechanisms of diseases, translational medical research targeting mTOR signaling, and drug discovery based on mTOR cascades. This Special Issue invites basic, preclinical, and translational advances in the diagnosis and treatment of mTOR-related disorders. Original research articles, reviews, and case reports illustrating unique clinical care within the scope of mTOR signaling are welcome. Research areas of interest include, but are not limited to, the following: bone metabolism, craniofacial and oral disorders, stem cells, novel targets in various therapeutic areas, cell/gene/target therapy, and oncology.

We look forward to receiving your contributions.

Dr. Wenjing Yu
Dr. Chider Chen
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• mTOR signaling
• tissue engineering
• stem cell
• disease
• therapy
• bone
• craniofacial
• biomedicine